Acousia Therapeutics GmbH: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
11.5.2022 10:03:28 CEST | news aktuell GmbH | Press release
(Tübingen, Germany): ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients. Designed to modulate a biologically validated target – the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function – ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss.
ACOU085 is characterized by a unique dual mode of action, which provides acute functional enhancement and long-term protection for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics. “I look forward to stimulating discussions with our peers in Boston.”
In addition to receiving an invitation to present “Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment and Prevention of Hearing Loss”, Dr. Dyhrfjeld-Johnsen will also participate as a panelist on the panel discussion “De-risking the Early Development Process: A Robust and Comprehensive Early Development Process Is Essential to Minimize Setbacks Faced in the Clinic” and in the workshop “Mind The Gap: Calling Out the Shortfalls in the Current Inner Ear Therapeutic Development Pathway and Illuminating Solutions”.
About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.
Contacts
Tim Boelke,
M.D.
boelke@acousia.com
+49 70712988186
www.acousia.com
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
HEIDELBERG systematically pressing ahead with strategic development – solid start to FY 2026/202719.8.2026 09:02:17 CEST | Press release
Taking over manroland sheetfed lifecycle business and POLAR production operations strengthens core business ONBERG pursuing partnership with Skyeton in European defense sector Move into production of sodium-ion battery storage systems taps into new potential First-quarter incoming orders lay solid foundation for further business development Sales and EBITDA margin at start of year in line with expectations Forecast for financial year 2026/2027 confirmed
Polarise secures further debt financing to expand its European AI cloud platform18.8.2026 11:47:20 CEST | Press release
Düsseldorf, 18. August 2026 – Polarise Holding GmbH (“Polarise”), a European provider of sovereign AI cloud solutions, has secured a debt financing partnership with SWI Stoneweg Icona Group (“SWI Group”) to accelerate the expansion of its European AI cloud platform. The financing of up to a high double-digit million-euro amount strengthens Polarise’s funding base for the continued execution of its growth strategy. As part of the new financing structure, Polarise and SWI Group have agreed to transition the previously announced majority equity investment agreement into a debt financing arrangement. Michel Boutouil, CEO of Polarise, said: “Our growth strategy is aimed at building Europe’s AI infrastructure of the future – with sustainable, highly efficient AI Factories and sovereign AI compute for businesses. We are executing this strategy with significant momentum and strong partners. Polarise develops and operates AI data centres – so-called AI Factories – in Germany and across Europe.
Central Council calls for prevention through education and awareness-raising3.8.2026 09:19:17 CEST | Press release
Commemorative event to mark the European Holocaust Remembrance Day for Sinti and Roma on 2 August 2026 in Auschwitz-Birkenau
CHRIST chooses fulfillmenttools and commercetools for a future-proof commerce architecture31.7.2026 12:47:56 CEST | Press release
Cologne – CHRIST Juweliere und Uhrmacher, one of Europe's most renowned jewelry retailers, is partnering with fulfillmenttools to transform the way it manages and orchestrates orders across its retail network. CHRIST is implementing the Agentic Order Management System (OMS) – as part of a broader transformation in which the retailer is building a modular, future-proof commerce architecture powered by commercetools Sphere, the autonomous commerce platform. The new system landscape spans stores and digital channels across Germany, Austria and the Netherlands. Breaking free from monolithic constraints For internationally operating retailers, the ability to respond flexibly and quickly to customer demand is a key success factor. This is especially true in the jewellery trade, which is shaped by specific requirements: high-value products, complex inventory structures, and customers who expect a first-class, seamless shopping experience at every touchpoint. CHRIST has built a strong operatio
Bikeleasing Group announces strategic investment in New Zealand’s leading bike leasing company Workride / Next strategic step in cross-continental expansion29.7.2026 14:18:02 CEST | Press release
The Bikeleasing Group announces strategic investment in Workride, New Zealand’s market leader for company bike leasing as an employee benefit. Around 2,000 New Zealand employers already use Workride’s offering. The investment extends the Bikeleasing Group’s international presence and marks its next cross-continental step in its growth trajectory.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom